Monthly Archives: October 2012

Doctors' Stand Against Pricey Drugs: A Warning to Pharma?

By Amy Ritter. In a New York Times op-ed this week, a trio of physicians from the Memorial Sloan Kettering Cancer Center in New York announced their decision to remove an expensive new cancer treatment from the hospital formulary, citing cost-benefit as their reason. The physicians said that because Zaltrap (ziv-aflibercept) made by Sanofi/Regeneron was […]
Posted in Global | Tagged , | 1 Comment

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Tagged , , , , , | 1 Comment

Video: Should Pharmacies Be Held to the Same FDA Standards?

Posted in compliance, Corporate Responsibility, FDA, Manufacturing, News, Strategy | 1 Comment

What the Affordable Care Act Means for Pharma Marketing

By Gregg DiPietro. With the Supreme Court’s decision in June to uphold the Patient Protection and Affordable Care Act (ACA), life science companies gained access to 32 million potential new customers. While that’s worth celebrating, the party may have ended before it began. For pharmaceutical companies to realize the benefits of new healthcare consumers, and […]
Posted in Guest Blog, Regulatory, Strategy | Tagged , , , , , | Leave a comment

Compounded Drug Crisis Spotlights Regulatory Confusion

Compounded drug crisis spotlights regulatory confusion The call for stiffer FDA regulation of compounded drugs has been reignited by a national fungal meningitis outbreak. Last week, the Centers for Disease Control and Prevention (CDC) reported 7 deaths linked to contaminated vials of steroid injectables from a Massachusetts compounding operation. 91 people have been taken ill, […]
Posted in FDA, Op-Ed, Safety | Tagged , , , , | 1 Comment
  • Categories

  • Meta